The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: OneSavings Upped To Buy, Aldermore Cut To Hold

Thu, 26th Nov 2015 09:45

LONDON (Alliance News) - The following shares received analyst recommendations Thursday morning and Wednesday:
----------
FTSE 100
----------
PANMURE LEAVES SAGE GROUP AT 'HOLD' - TARGET 535 PENCE
----------
RBC CAPITAL CUTS AVIVA TO 'UNDERPERFORM' ('SECTOR PERFORM') - TARGET 460 (490)P
----------
NOMURA RAISES COMPASS GROUP PRICE TARGET TO 1,240 (1,162) PENCE - 'BUY'
----------
DEUTSCHE BANK CUTS COMPASS GROUP PRICE TARGET TO 1,250 (1,330) PENCE - 'BUY'
----------
JPMORGAN CUTS BHP BILLITON TO 'UNDERWEIGHT' ('NEUTRAL') - PRICE TARGET 750 (1300) P
----------
SOCGEN CUTS BHP BILLITON PRICE TARGET TO 915 (1050) PENCE - 'HOLD'
----------
UBS RAISES BAE SYSTEMS PRICE TARGET TO 580 (510) PENCE - 'BUY'
----------
TRADERS: HSBC ADDS ROYAL DUTCH SHELL TO 'EUROPE SUPER TEN'
----------
RBC CAPITAL MARKETS UPS BG GROUP TO OUTPERFORM FROM SECTOR PERFORM
----------
S&P CAPITAL IQ CUTS STANDARD CHARTERED PRICE TARGET TO 530 (650) PENCE - 'SELL'
----------
GOLDMAN RAISES UNILEVER PLC PRICE TARGET TO 2760 (2415) PENCE - 'SELL'
----------
GOLDMAN RAISES RECKITT BENCKISER PRICE TARGET TO 6345 (6170) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES DIAGEO PRICE TARGET TO 1685 (1600) PENCE - 'SELL'
----------
GOLDMAN RAISES BAT PRICE TARGET TO 3700 (3210) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES IMPERIAL TOBACCO PRICE TARGET TO 3900 (3700) P - 'CONVICTION BUY'
----------
MORGAN STANLEY CUTS HARGREAVES LANSDOWN TO 'EQUAL-WEIGHT' ('OW')- TARGET 1,345P
----------
MORGAN STANLEY RAISES SCHRODERS TARGET TO 3,175 (2,990) PENCE - 'EQUAL-WEIGHT'
----------
MORGAN STANLEY RAISES ABERDEEN ASSET MANAGEMENT TARGET TO 300 (292) P - 'UW'
----------
MORGAN STANLEY RAISES 3I GROUP PRICE TARGET TO 517 (382) PENCE - 'EQUAL-WEIGHT'
----------
FTSE 250
----------
RBC CAPITAL RAISES RPC GROUP PRICE TARGET TO 780 (700) PENCE - 'OUTPERFORM'
----------
JPMORGAN RAISES RPC GROUP PRICE TARGET TO 850 (829) PENCE - 'OVERWEIGHT'
----------
DEUTSCHE BANK RAISES RPC GROUP PRICE TARGET TO 760 (730) PENCE - 'BUY'
----------
LIBERUM CUTS PARAGON GROUP PRICE TARGET TO 482 (512) PENCE - 'BUY'
----------
N+1 Lifts Spectris To Hold From Sell, Cuts Target To 1,770p From 2,070p
----------
Investec Upgrades OneSavings Bank To Buy From Hold, Target At 375p
----------
DEUTSCHE BANK CUTS ALDERMORE TO 'HOLD' ('BUY') - TARGET 267 (330) PENCE
----------
Berenberg Cuts Greencore Group Target To 380p From 390p, Keeps Buy
----------
Liberum Cuts Senior Price Target To 255p From 295p, Keeps Hold
----------
Liberum Downgrades Ultra Electronics Holdings To Hold From Buy; Lifts Price Target To 1,950p From 1,900p
----------
UBS RAISES ULTRA ELECTRONICS PRICE TARGET TO 1,950 (1,850) PENCE - 'NEUTRAL'
----------
UBS CUTS PLAYTECH PRICE TARGET TO 960 (990) PENCE - 'BUY'
----------
UBS RAISES QINETIQ PRICE TARGET TO 225 (205) PENCE - 'SELL'
----------
UBS RAISES COBHAM PRICE TARGET TO 300 (280) PENCE - 'NEUTRAL'
----------
DEUTSCHE BANK RAISES BRITVIC PRICE TARGET TO 775 (750) PENCE - 'HOLD'
----------
SOCGEN RAISES BRITVIC PRICE TARGET TO 870 (760) PENCE - 'BUY'
----------
GOLDMAN RAISES BRITVIC PRICE TARGET TO 833 (795) PENCE - 'CONVICTION BUY LIST'
----------
BERENBERG RAISES SUPERGROUP PRICE TARGET TO 1,800 (1,390) PENCE - 'BUY'
----------
SOCGEN RAISES DAIRY CREST GROUP PRICE TARGET TO 620 (490) PENCE - 'HOLD'
----------
GOLDMAN RAISES DAIRY CREST GROUP PRICE TARGET TO 550 (380) PENCE - 'SELL'
----------
BARCLAYS RAISES BETFAIR PRICE TARGET TO 4,000 (3,420) PENCE - 'OVERWEIGHT'
----------
GOLDMAN RAISES PZ CUSSONS PRICE TARGET TO 360 (355) PENCE - 'BUY'
----------
GOLDMAN RAISES TATE & LYLE PRICE TARGET TO 615 (470) PENCE - 'NEUTRAL'
----------
BERENBERG CUTS SPIRE HEALTHCARE PRICE TARGET TO 365 (390) PENCE - 'BUY'
----------
MORGAN STANLEY RAISES HENDERSON GROUP TARGET TO 330 (300) PENCE - 'OVERWEIGHT'
----------
MORGAN STANLEY RAISES ASHMORE GROUP TARGET TO 251 (247) P - 'EQUAL-WEIGHT'
----------
MAIN MARKET AND AIM
----------
EXANE BNP CUTS DAILY MAIL PRICE TARGET TO 720 (850) PENCE - 'NEUTRAL'
----------
NOMURA CUTS DAILY MAIL PRICE TARGET TO 800 (865) PENCE - 'NEUTRAL'
----------
SOCGEN RAISES DAILY MAIL TO 'HOLD' ('SELL') - TARGET 725 PENCE
----------
BARCLAYS CUTS DAILY MAIL PRICE TARGET TO 830 (850) PENCE - 'OVERWEIGHT'
----------
DEUTSCHE BANK CUTS DAILY MAIL PRICE TARGET TO 750 (830) PENCE - 'HOLD'
----------
JPMORGAN CUTS HSS HIRE TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 60 (180) PENCE
----------
BERENBERG CUTS HSS HIRE PRICE TARGET TO 43 (60) PENCE - 'HOLD'

----------

Northland Capital Initiated Evgen Pharma With Buy, Target At 79p
----------
Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 20:57

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 15:59

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.

Read more
19 Feb 2024 11:45

Evgen Pharma shares up on studies into SFX-01 product progressing well

(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.

Read more
9 Feb 2024 18:53

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
9 Feb 2024 17:02

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

Read more
16 Jan 2024 18:59

IN BRIEF: Evgen partner raises USD17.4 million to support pipeline

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.

Read more
22 Dec 2023 18:06

IN BRIEF: Evgen appoints Toni Hanninen as permanent CFO

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.

Read more
31 Oct 2023 14:38

TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:

Read more
26 Oct 2023 11:08

Evgen upbeat on start of glioblastoma research project

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Read more
19 Oct 2023 19:39

IN BRIEF: Evgen showcases importance of new enteric-coated formulation

Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
15 Aug 2023 10:01

Evgen Pharma says trial shows new SFX-01 drug formulation is safe

(Alliance News) - Evgen Pharma PLC on Tuesday said final data from a trial of its SFX-01 therapy has shown a new formulation of the drug is safe.

Read more
2 Aug 2023 10:28

IN BRIEF: Evgen Pharma shares drop on ending of license agreement

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focused on developing sulforaphane-based medicines - Terminates the patent and know-how license agreement for its Sulforadex sulforaphane stabilisation technology with partner JuvLife Ltd. The exclusive rights will be returned in the final quarter of 2023. The already received upfront payment is non-refundable.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.